Voya Investment Management LLC Sells 45,352 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Voya Investment Management LLC lessened its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 48.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 48,831 shares of the company's stock after selling 45,352 shares during the quarter. Voya Investment Management LLC owned approximately 0.06% of Syndax Pharmaceuticals worth $646,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of SNDX. E Fund Management Co. Ltd. raised its holdings in Syndax Pharmaceuticals by 14.4% in the 4th quarter. E Fund Management Co. Ltd. now owns 12,603 shares of the company's stock worth $167,000 after purchasing an additional 1,583 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in Syndax Pharmaceuticals by 10.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,099 shares of the company's stock valued at $239,000 after buying an additional 1,732 shares during the period. R Squared Ltd bought a new position in shares of Syndax Pharmaceuticals during the 4th quarter valued at approximately $26,000. Y Intercept Hong Kong Ltd increased its stake in Syndax Pharmaceuticals by 2.5% in the 4th quarter. Y Intercept Hong Kong Ltd now owns 83,297 shares of the company's stock worth $1,101,000 after buying an additional 1,995 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Syndax Pharmaceuticals by 1.2% in the fourth quarter. Bank of New York Mellon Corp now owns 224,261 shares of the company's stock worth $2,965,000 after buying an additional 2,759 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on SNDX. Guggenheim reiterated a "buy" rating and issued a $32.00 target price on shares of Syndax Pharmaceuticals in a report on Tuesday, May 6th. StockNews.com raised shares of Syndax Pharmaceuticals to a "sell" rating in a report on Tuesday, May 6th. Citigroup lowered their price objective on Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. Scotiabank boosted their price objective on Syndax Pharmaceuticals from $16.00 to $17.00 and gave the company a "sector perform" rating in a research report on Tuesday, May 6th. Finally, JPMorgan Chase & Co. raised their price target on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an "overweight" rating in a research note on Thursday, March 20th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $35.91.

Syndax Pharmaceuticals Trading Down 7.3%

SNDX stock traded down $0.80 during mid-day trading on Tuesday, reaching $10.19. 1,537,727 shares of the stock traded hands, compared to its average volume of 1,691,870. The stock's fifty day moving average is $12.41 and its 200-day moving average is $14.30. The company has a market cap of $876.82 million, a P/E ratio of -2.81 and a beta of 0.82. Syndax Pharmaceuticals, Inc. has a 52-week low of $9.66 and a 52-week high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.04) by $0.06. The firm had revenue of $20.04 million for the quarter, compared to analyst estimates of $15.88 million. During the same quarter in the prior year, the firm earned ($0.85) earnings per share. The firm's quarterly revenue was up 1900.0% compared to the same quarter last year. Equities research analysts expect that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).